British Journal of Cancer - Table of Contents alert Volume 115 Issue 8

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 115, Issue 8 (909-1016) Published online 11 October 2016 In this issue Editorial Clinical Studies Translational Therapeutics Molecular Diagnostics Genetics and Genomics Letters to the Editor Also new today Advance online publication Digital Edition Sign up for e-alerts Recommend to your library Web feed Subscribe Editorial Top Renewed interest in the progesterone receptor in breast cancer Elgene Lim, Carlo Palmieri and Wayne D Tilley Br J Cancer 2016 115: 909-911; advance online publication, September 22, 2016; 10.1038/bjc.2016.303 Full Text Clinical Studies Top Persistence to 5-year hormonal breast cancer therapy: a French national population-based study Pauline Bosco-Lévy, Jeremy Jové, Philip Robinson, Nicholas Moore, Annie Fourrier-Réglat and Julien Bezin Br J Cancer 2016 115: 912-919; advance online publication, September 6, 2016; 10.1038/bjc.2016.276 Abstract | Full Text Translational Therapeutics Top MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model C Marcela Diaz-Montero, Frances J Mao, John Barnard, Yvonne Parker, Maryam Zamanian-Daryoush, John J Pink, James H Finke, Brian I Rini and Daniel J Lindner Br J Cancer 2016 115: 920-928; advance online publication, August 25, 2016; 10.1038/bjc.2016.263 Abstract | Full Text Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition Marte Jonsson, Harald Bull Ragnum, Cathinka Halle Julin, Andree Yeramian, Trevor Clancy, Kari-Anne Myrum Frikstad, Therese Seierstad, Trond Stokke, Xavier Matias-Guiu, Anne Hansen Ree, Kjersti Flatmark and Heidi Lyng Br J Cancer 2016 115: 929-939; advance online publication, September 6, 2016; 10.1038/bjc.2016.278 Abstract | Full Text A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer Madelon Q Wentink, Henk J Broxterman, Siu W Lam, Epie Boven, Maudy Walraven, Arjan W Griffioen, Roberto Pili, Hans J van der Vliet, Tanja D de Gruijl and Henk M W Verheul Br J Cancer 2016 115: 940-948; advance online publication, August 30, 2016; 10.1038/bjc.2016.275 Abstract | Full Text Molecular Diagnostics Top Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags Kazuyuki Sogawa, Shigetsugu Takano, Fumie Iida, Mamoru Satoh, Sachio Tsuchida, Yusuke Kawashima, Hideyuki Yoshitomi, Akihiro Sanda, Yoshio Kodera, Hirotaka Takizawa, Rintaro Mikata, Masayuki Ohtsuka, Hiroaki Shimizu, Masaru Miyazaki, Osamu Yokosuka and Fumio Nomura Br J Cancer 2016 115: 949-956; advance online publication, September 22, 2016; 10.1038/bjc.2016.295 Abstract | Full Text Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours Ciputra Adijaya Hartana, Johan Kinn, Robert Rosenblatt, Stefan Anania, Farhood Alamdari, Hans Glise, Amir Sherif and Ola Winqvist Br J Cancer 2016 115: 957-966; advance online publication, September 6, 2016; 10.1038/bjc.2016.279 Abstract | Full Text The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone Esther J Campbell, Mathias Tesson, Flora Doogan, Zahra MA Mohammed, Elizabeth Mallon and Joanne Edwards Br J Cancer 2016 115: 967-973; advance online publication, September 22, 2016; 10.1038/bjc.2016.206 Abstract | Full Text Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab Charles S Fuchs, Josep Tabernero, Jiří Tomášek, Ian Chau, Bohuslav Melichar, Howard Safran, Mustapha A Tehfe, Dumitru Filip, Eldar Topuzov, Luis Schlittler, Anghel Adrian Udrea, William Campbell, Stephen Brincat, Michael Emig, Symantha A Melemed, Rebecca R Hozak, David Ferry, C William Caldwell and Jaffer A Ajani Br J Cancer 2016 115: 974-982; advance online publication, September 13, 2016; 10.1038/bjc.2016.293 Abstract | Full Text p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma Raheela Awais, David G Spiller, Michael R H White and Luminita Paraoan Br J Cancer 2016 115: 983-992; advance online publication, September 1, 2016; 10.1038/bjc.2016.269 Abstract | Full Text Ovarian carcinoma diagnosis: the clinical impact of 15 years of change Stefan Kommoss, C Blake Gilks, Andreas du Bois and Friedrich Kommoss Br J Cancer 2016 115: 993-999; advance online publication, September 15, 2016; 10.1038/bjc.2016.273 Abstract | Full Text Genetics and Genomics Top Gene expression profiling identifies distinct molecular subgroups of leiomyosarcoma with clinical relevance Yin-Fai Lee, Toby Roe, D Chas Mangham, Cyril Fisher, Robert J Grimer and Ian Judson Br J Cancer 2016 115: 1000-1007; advance online publication, September 8, 2016; 10.1038/bjc.2016.280 Abstract | Full Text Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia G Bogdanovic, C Pou, M Barrientos-Somarribas, A Bjerkner, E Honkaniemi, T Allander, B Andersson and B Gustafsson Br J Cancer 2016 115: 1008-1014; advance online publication, August 23, 2016; 10.1038/bjc.2016.261 Abstract | Full Text Letters to the Editor Top Comment on ‘The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome’ Claude Lentschener, Carole Nicco, Benoit Terris, Charles-Marc Samama and Romain Coriat Br J Cancer 2016 115: e7; advance online publication, September 15, 2016; 10.1038/bjc.2016.242 Full Text Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome'’ S M Robinson, D A Mann, D M Manas, F Oakley, J Mann and S A White Br J Cancer 2016 115: e8; advance online publication, September 15, 2016; 10.1038/bjc.2016.268 Full Text How should performance in EBUS mediastinal staging in lung cancer be measured? Matthew Evison, Philip Crosbie, Neal Navani, Matthew Callister, Robert C Rintoul, David Baldwin and Richard Booton Br J Cancer 2016 115: e9; advance online publication, August 23, 2016; 10.1038/bjc.2016.253 Full Text Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.